Tocilizumab promotes repair of spinal cord injury by facilitating the restoration of tight junctions between vascular endothelial cells
ConclusionThe application of Tocilizumab to antagonize IL-6R can effectively reduce the expression of IL-6 in macrophages and facilitate TJs restoration of the BSCB, which is beneficial for axon regeneration and motor functional recovery after SCI. Hence, Tocilizumab treatment is a potential therapeutic strategy for SCI.
Source: Fluids and Barriers of the CNS - Category: Neuroscience Source Type: research
More News: Actemra | Brain | Gastroschisis Repair | Neurology | Neuroscience | Spinal Cord Injury | Study